Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

doi:10.18632/oncotarget.16057

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Oncotarget - 18 Apr 2017

Bryce Alan H, Egan Jan B, Borad Mitesh J, Stewart A Keith, Nowakowski Grzegorz S, Chanan-Khan Asher, Patnaik Mrinal M, Ansell Stephen M, Banck Michaela S, Robinson Steven I, Mansfield Aaron S, Klee Eric W, Oliver Gavin R, McCormick Jennifer B, Huneke Norine E, Tagtow Colleen M, Jenkins Robert B, Rumilla Kandelaria M, Kerr Sarah E, Kocher Jean-Pierre A, Beck Scott A, Fernandez-Zapico Martin E, Farrugia Gianrico, Lazaridis Konstantinos N, McWilliams Robert R

Abstract excerpt

BACKGROUND: The ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory to standard therapy. At Mayo Clinic these efforts are organized through the Center for Individualized Medicine (CIM). RESULTS: Prior to GTB, datasets were analyzed and integrated by a team of bioinformaticians and cancer biologists. Therapeutically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Computational Biology

Share to Genomics

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28423702
DOI: 10.18632/oncotarget.16057
PMCID: PMC5432324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.PMID 28423702Read ↗

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health systemSemantic proximity Read ↗

Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer MedicineSemantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceSemantic proximity Read ↗

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read ↗

Clinical application of whole-genome sequencing for precision oncology of solid tumorsSemantic proximity Read ↗

Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.Semantic proximity Read ↗

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.Semantic proximity Read ↗

Unlocking precision oncology by establishing a nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer: the BALLETT studySemantic proximity Read ↗

Clinical application of whole-genome sequencing of solid tumors for precision oncology.Semantic proximity Read ↗

Precision oncology based on omics data: The NCT Heidelberg experienceSemantic proximity Read ↗

Molecular Tumor Board: The University of California San Diego Moores Cancer Center ExperienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.